MTOR and ovarian carcinoma: This study presents the novel combination of a PI3K/mTOR inhibitor and an ERK inhibitor as a potential treatment for ovarian cancer and directly compares the effect of these inhibitors in both monolayer and three-dimensional in vitro ovarian cancer models.